Clinical trials: Metastatic Solid Tumor Cancer
NSCLC, Solid Tumor
A Phase Ib Study With Pegylated Recombinant Human Endostatin in Advanced / Metastatic NSCLC or Other Solid Tumors
The primary purpose of this study is to examine the safety, tolerability and pharmacokinetics of PEG-ENDO in combination with docetaxel in subjects previously treated or untreated (standard therapy is not suitable or without…
- Trial name
- NCT04413227
- Testing
- Pegylated Recombinant Human Endostatin（PEG-ENDO）
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer, Advanced/Metastatic
Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC
This is a two-part, biomarker-guided Phase 1/2 study evaluating the safety, feasibility, and preliminary anti-tumor activity of off-the-shelf dual-target CAR-NK cells in participants with advanced or metastatic NSCLC whose tumors…
- Trial name
- DUO-NK-NSCLC (NCT07641023)
- Testing
- Dual-target CAR-NK cells, Lymphodepleting chemotherapy, Supportive care
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Biotech
Unspecified Adult Solid Tumor, Protocol Specific
SB939 in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: SB939 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of SB939 in treating patients with locally…
- Trial name
- NCT00504296
- Testing
- HDAC inhibitor SB939, immunoenzyme technique, immunohistochemistry staining method
- Where
- 2 sites in Canada
- Volunteers
- 39 people
- Sponsor
- NCIC Clinical Trials Group
Locally Advanced or Metastatic Solid Tumors
Study of AMV564 in Subjects With Advanced Solid Tumors
This Phase 1 study is designed to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of AMV564 alone and in combination with Pembrolizumab in patients with advanced solid tumors.
- Trial name
- NCT04128423
- Testing
- AMV564
- Where
- 11 sites in United States
- Volunteers
- 65 people
- Sponsor
- Amphivena Therapeutics, Inc.
Advanced Solid Tumor, Metastatic Solid Tumor
A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-108, as a single agent, in patients with advanced or metastatic solid tumors
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Cancer (NSCLC), Head and Neck (HNSCC)
- Trial name
- NCT07172802
- Testing
- GI-108
- Where
- 3 sites in South Korea
- Volunteers
- 102 people
- Sponsor
- GI Innovation, Inc.
Solid Tumors, Cancer
Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer
The purpose of this study is to evaluate the safety profile, tolerability, pharmacokinetics (PK), pharmacodynamics, pharmacogenomic (PGX) and preliminary efficacy following daily oral doses of cabozantinib (XL184) in Japanese…
- Conditions
- Solid Tumors, Cancer, NSCLC
- Trial name
- NCT01553656
- Testing
- cabozantinib capsules, cabozantinib tablets
- Where
- 2 sites in Japan
- Volunteers
- 85 people
- Sponsor
- Exelixis
Solid Tumor Cancer, Metastatic Solid Tumors
A Multicenter, Prospective, Non-Interventional Real-World Study of Iparomlimab and Tuvonralimab Injection (QL1706) in the Treatment of Locally Advanced or Metastatic Solid Tumors
This study is a prospective, observational, real-world, multi-center study planning to enroll 90 patients. The study will observe and document patients' actual clinical practices in receiving Iparomlimab and Tuvonralimab…
- Conditions
- Solid Tumor Cancer, Metastatic Solid Tumors, Locally Advanced
- Trial name
- NCT07046780
- Testing
- Observation arm
- Where
- China
- Volunteers
- 90 people
- Sponsor
- PENG YUAN
Advanced Cancer
Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC
Mocetinostat (MGCD0103) is an orally administered HDAC inhibitor. Durvalumab (MEDI4736) is a human monoclonal antibody that is an inhibitor of the Programmed Cell Death Ligand (or PD-L1).
- Trial name
- NCT02805660
- Testing
- Mocetinostat - 50 mg, Mocetinostat - 70 mg, Mocetinostat - 90 mg
- Where
- 15 sites in United States
- Volunteers
- 83 people
- Sponsor
- Mirati Therapeutics Inc.
Solid Tumors
A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors
This is a first-in-human, open-label, uncontrolled, multi-center, monotherapy dose-escalation and dose expansion study of RO7444973.The aim of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and…
- Trial name
- NCT05129280
- Testing
- RO7444973, Tocilizumab
- Where
- 10 sites in United States, Australia and 4 more
- Volunteers
- 23 people
- Sponsor
- Hoffmann-La Roche
Solid Tumors
A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid Tumors
A phase 1 open-label dose escalation study of OMP-21M18 in subjects with previously treated solid tumour for which there is no remaining standard curative therapy and no therapy with a demonstrated survival benefit.
- Trial name
- NCT00744562
- Testing
- OMP-21M18
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Locally Advanced or Metastatic Solid Tumors
Clinical Trial to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors
This study is an Open-Label, Phase 1/2a, First-in-Human, Dose-Escalation, Dose-Expansion, and Proof-of-Concept Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single…
- Trial name
- NCT06293651
- Testing
- DA-4505, DA-4505 + Pembrolizumab
- Where
- 2 sites in South Korea
- Volunteers
- 125 people
- Sponsor
- Dong-A ST Co., Ltd.
Unspecified Adult Solid Tumor, Protocol Specific
Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment
RATIONALE: Drugs used in chemotherapy, such as hydroxychloroquine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00909831
- Testing
- hydroxychloroquine, temsirolimus, electron microscopy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain
RATIONALE: An Opioid Titration Order Sheet that allows healthcare providers to adjust the dose and schedule of pain medication may help improve pain treatment for patients with cancer.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00666211
- Testing
- educational intervention, Titrated pain management, questionnaire administration
- Where
- 11 sites in United States
- Volunteers
- 98 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Adult Giant Cell Glioblastoma, Adult Glioblastoma
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study participants with glioblastoma multiforme…
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Male Breast Cancer
- Trial name
- NCT01806675
- Testing
- 18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sanjiv Sam Gambhir
Neoplasm Metastasis
Study of DS-8201a for Participants With Advanced Solid Malignant Tumors
HER2-positive cancer is a cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2). HER2 promotes the growth of certain cancer cells.
- Trial name
- NCT03383692
- Testing
- DS-8201a, Ritonavir, Itraconazole
- Where
- 10 sites in Japan, South Korea and 1 more
- Volunteers
- 40 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Malignant Neoplasm
A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)
The goal of this study is to learn about the safety of different doses of MK-4700 and if people tolerate them. The study will also measure what happens in a person's body over time when MK-4700 is given alone or with…
- Trial name
- NCT06894771
- Testing
- MK-4700, Pembrolizumab
- Where
- 7 sites in United States, Canada and 1 more
- Volunteers
- 5 people
- Sponsor
- Merck Sharp & Dohme LLC
Locally Advanced or Metastatic Solid Tumors
A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors
This is a study of ATG-037 Monotherapy and Combination Therapy with Pembrolizumab in Patients with Locally Advanced or Metastatic Solid Tumors
- Trial name
- NCT05205109
- Testing
- ATG-037, KEYTRUDA ®( Pembrolizumab)
- Where
- 7 sites in Australia, China
- Volunteers
- 98 people
- Sponsor
- Antengene Therapeutics Limited
Advanced Solid Tumor, Metastatic Solid Tumor
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
This interventional study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ART6043 as monotherapy or in combination with olaparib.
- Trial name
- NCT05898399
- Testing
- ART6043, Olaparib
- Where
- 27 sites in United States, Spain and 1 more
- Volunteers
- 181 people
- Sponsor
- Artios Pharma Ltd
CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
This is a study of CDX-1127, a therapy that targets the immune system and may act to promote anti-cancer effects. The study enrolls patients with hematologic cancers (certain leukemias and lymphomas), as well as patients with…
- Conditions
- CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone B Cell Lymphoma)
- Trial name
- NCT01460134
- Testing
- CDX-1127
- Where
- 10 sites in United States
- Volunteers
- 90 people
- Sponsor
- Celldex Therapeutics
Advanced/Metastatic Solid Tumors, Neoplasms
Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)
The purpose of this study is to assess the safety, pharmacokinetics, and preliminary efficacy of MK-4464 as monotherapy and in combination with pembrolizumab in participants with advanced/metastatic solid tumors.
- Trial name
- NCT05514444
- Testing
- MK-4464, Pembrolizumab, 89Zr-MK-4464
- Where
- 6 sites in United States, Canada and 2 more
- Volunteers
- 64 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.